A Facile Method to Engineer Mutant Kras Alleles in an Isogenic Cell Background

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• Oncogenic KRAS mutations are prevalent in colorectal cancer (CRC), impacting prognosis and treatment response.
• Significant diversity exists among KRAS mutations, with specific alleles (e.g., G12, G13, A146, Q61) influencing disease characteristics.
• Understanding these allele-specific differences is crucial for developing targeted colorectal cancer therapies.

Purpose of the Study:

• To develop a novel, efficient method for generating various KRAS mutations in an isogenic cellular background.
• To facilitate the study of allele-specific KRAS mutation effects on colorectal cancer biology and treatment.
• To enable the exploration of individualized therapeutic strategies based on specific KRAS mutations.

Main Methods:

• Utilized CRISPR-Cas9 gene editing with fluorescent co-selection (BFP and GFP) for efficient homologous recombination (HDR).
• Developed an assay to introduce specific KRAS mutant alleles into a murine colon epithelial cell line.
• Enabled the generation of isogenic cell lines with distinct, phenotypically silent KRAS mutations while preserving the wild-type allele.

Main Results:

• Successfully established a CRISPR-driven assay for generating diverse KRAS mutations in isogenic murine colon epithelial cells.
• The fluorescent co-selection system (GFP-positive selection) effectively identifies cells with successful HDR and desired KRAS edits.
• The method allows for precise manipulation of KRAS alleles within an isogenic framework, preserving the wild-type allele.

Conclusions:

• The developed assay provides a powerful tool for investigating the functional consequences of specific KRAS mutations in colorectal cancer.
• This approach supports the study of allele-specific differences, paving the way for personalized medicine in CRC.
• The ability to generate and study various KRAS mutant alleles in an isogenic background is key to advancing our understanding of CRC pathogenesis and treatment.